Beyond Biotech - the podcast from Labiotech

Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRNA — each still has to be engineered disease by disease. Alltrna is testing a different idea: that the real target isn't the gene, but the process of translation itself, where genetic instructions become protein. The company's lead approach focuses on nonsense mutations, a shared error responsible for roughly a tenth of all genetic disease diagnoses, and asks whether a single engineered molecule could address it across many conditions at once. My guest today is Dr. Nerissa Kreher, Chief Medical Officer of Alltrna . Nerissa brings two decades of rare disease drug development experience, including CMO roles at Entrada Therapeutics, Tiburio Therapeutics, and AVROBIO, to the task of turning that platform thesis into an actual clinical program. We'll talk translation, trial design, and what it takes to bring the first engineered tRNA therapy into the clinic. 02:45 Meet Nerissa Kreher and Alltrna's tRNA platform 07:29 Gene-by-gene versus mutation-by-mutation drug development 12:08 What nonsense mutations are and why they matter 15:55 Phase 1 trial approval in Australia 19:49 What basket trials are and FDA receptiveness 27:27 Where Alltrna could be in five years Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Beyond Biotech - Episode 66: treating rare diseases with tRNA Will tRNA therapy be the next big thing in genetic disease treatment? Pharma giants pull back on AAV research: what’s next for the gene therapy space?

Gene therapy has largely stayed out of the brain, and the blood-brain barrier has been the reason why — it protects the brain from harm, but it also blocks most advanced medicines from ever reaching it. That's now beginning to change. The recent FDA approval of a brain-penetrant enzyme therapy for Hunter syndrome showed that biologics can cross that barrier and work. The next question is whether gene editing can do the same. My guest today is Dr. Per Lundin, Co-Founder and CEO of Evox Therapeutics , a UK biotech using engineered exosomes to deliver genetic medicines directly into the brain. Evox is now extending that platform from RNA and biologics into gene editing, targeting the genetic drivers of diseases like Huntington's and ALS, where treatment options remain extremely limited. Per also brings a background as a European Patent Attorney and repeat biotech founder. We'll talk delivery, pipeline, and what a commercially scalable genetic medicine for the brain might actually look like. 02:45 Per Lundin's background and Evox's platform 09:38 Denali's Hunter syndrome approval and its significance 14:58 Targeting MSH3 to treat Huntington's disease 20:03 What commercially scalable genetic medicine requires 22:13 Evox's dominant IP position in exosome delivery 27:34 What success could mean for patients in ten years Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Evox and Lilly Partner to Develop Neuro RNA Drugs in Deal Worth €1.1B Six exosome therapy companies driving development in the field Extracellular vesicles: a growing pipeline still searching for validation

Today we’re thrilled to bring you a special episode highlighting one of Europe’s premier biotechnology events: BIOSPAIN 2026. Joining us is Stuart Medina of Asebio, who will take us inside this landmark gathering. For the first time and in response to strong sector demand and growing interest, BIOSPAIN moves to an annual format. Hosted this year in vibrant Bilbao in Spain’s dynamic Basque Country, the event runs from 29 September to 1 October at the Bilbao Exhibition Centre. In this episode we explore the BIOSPAIN program, the partnering opportunities on offer, the new Talent Day on the final day, and all the practical and logistical details for attendees. 04:02 Why BIOSPAIN is moving to an annual format 05:17 Bilbao and the Basque country 09:44 BIOSPAIN 2026: four program tracks 13:47 One-on-one partnering 16:10 International participation and a growing Latin American presence 22:27 Talent Day: BIOSPAIN's dedicated biotech job fair 27:48 Ticket options, exhibiting, and sponsorship opportunities This episode is presented with the support of Asebio and BIOSPAIN. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Pharma in Spain: why global investors and innovators are moving in Practical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next step Episode 165 - BIOSPAIN 2025: Why 1000 companies from more than 40 countries will gather in Barcelona this year

What if the key to beating cancer wasn't a new drug, but a new way of thinking about matter itself? That's the question Laurent Lévy asked when he co-founded Nanobiotix over twenty years ago — and it's a question that is now producing some genuinely compelling answers in the clinic. Nanobiotix is a Paris-based biotech pioneering what they call physics-based nanomedicine. Their lead asset is a radioenhancer made of hafnium oxide nanoparticles, designed to be injected directly into a tumor and amplify the destructive power of radiotherapy from within — without increasing damage to surrounding healthy tissue. It is currently in Phase 3 trials in head and neck cancer. But that's only half the story. The company's Nanoprimer platform is now emerging as a potential new engine for growth — with the promise of making an entirely new class of genetic medicines work better. 02:47 Meet Laurent Lévy 06:04 What physics offers that biology cannot 11:12 How JNJ-1900 (NBTXR3) works 15:14 The immune effect 18:16 Pipeline milestones ahead 20:56 The Curadigm Nanoprimer platform 25:32 The oversubscribed €85 million raise Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Radiotherapy-Enhancing Cancer Nanomedicine Secures Good Phase II/III Results Get to know 15 of the best biotech companies in Paris Eight nanotechnology companies to watch out for

Cancer is still the leading cause of death by disease in children and young people — yet in the last twenty years, only a handful of drugs have been approved specifically to treat it. Most paediatric cancer treatments are simply adult drugs, repurposed, often at real long-term cost to the children who survive. Today's guest is working to change that, and much more besides. Tony Hickson is Chief Business Officer for Cancer Research Horizons , Cancer Research UK's innovation engine, responsible for turning early-stage science into new treatments, diagnostics, and start-up companies. Tony's career spans big pharma, university tech transfer, and now the translational front line of cancer research, and he's helped build dozens of spinouts along the way. We'll talk about why charity and pharma need each other more than ever, and about C-Further, a bold new push to finally build medicines made for children, not borrowed from adults. 01:25 Meet Tony Hickson 05:21 What sets Cancer Research Horizons apart from tech transfer offices 12:17 Myrix Bio's exit to Novartis, a standout story 15:54 Can patient benefit and commercial success align 28:53 Inside C-Further's first two therapeutic programs 41:19 How researchers and partners can get involved Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Episode 32: Cancer Research Horizons, Enterome, OncoHost, TrakCel, Turbine Cancer Research UK Deploys €700M to Foster Oncology Startups Cancer vaccines: 11 biotechs to keep an eye out for

RNA therapeutics has had its defining moments. Antisense oligonucleotides. siRNA. And then, of course, mRNA — which went from a niche academic curiosity to the backbone of a global vaccine program in a matter of months. The next chapter may be circular RNA. CircRNA is more stable than linear mRNA, longer-lasting in the body, and potentially re-dosable. And one company has quietly built what may be the most advanced independent circRNA platform in the world — and with barely a single line of English-language press coverage, until now. My guest today is Dr. Lu Gao, CEO of Therorna Inc., a clinical-stage biotech headquartered in Beijing and Shanghai. The company recently presented three posters at ASGCT in Boston, and their lead program has just entered a first-in-human trial. We're going to talk about the science, the clinical strategy, and why Western pharma hasn't paid enough attention to what's being built in China. 01:33 Meet Lu Gao and Therorna 09:29 How Therorna's approach differs 15:42 How TI-0032 reprograms T cells in the body 21:22 Off-the-shelf and re-dosable: what it means for patients 24:38 Why no Chinese biotech has landed a major in vivo deal 31:27 What a successful US IND clearance would mean Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: The therapeutic potential of circular RNA: Could it soon trump mRNA technology? mRNA, RNAi, circRNA, ASOs: A comparative guide to RNA therapeutics Therorna funding to accelerate circRNA-based platform

Today we welcome Gene Mack, President and CEO of Gain Therapeutics. With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene brings deep expertise in capital markets, strategy, and drug development. He joined Gain in 2024 and stepped into the CEO role in early 2025. Gain Therapeutics is a clinical-stage biotech pioneering next-generation allosteric small molecule therapies. Using its proprietary Magellan platform, which combines 3D structural biology and physics-based modeling, the company is unlocking novel treatments for challenging disorders. Their lead candidate is advancing toward Phase 2 as a potential first-in-class disease-modifying therapy for Parkinson’s disease, with promising Phase 1b data showing biomarker improvements and functional benefits. In this episode, we’ll explore Gene’s journey, Gain’s innovative strategy, the Parkinson’s landscape, and the future of AI in biotech. · 01:28 Meet Gene Mack · 11:15 GAIN's mission: disease modification over symptom relief · 17:07 Why existing Parkinson's therapies fall short · 22:39 Origins and evolution of the Magellan platform · 26:16 How AI changes drug discovery beyond just speed · 28:13 Phase 1b study design and open-label extension results · 32:09 Partnership strategy and path to Phase 2 · 35:29 Advice for leaders in neurodegeneration Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Promising biotechs in Maryland right now Beyond amyloid and dopamine: emerging technologies reshaping neurology Neurological diseases R&D trends and breakthrough innovations

Epidermolysis bullosa, or EB, is one of those diseases that stops you in your tracks the moment you understand it. Skin so fragile that the gentlest touch can cause blisters and open wounds. No cure. And for most of its history, very little serious drug development attention. That's where today's guest comes in. Martin Steiner is Managing Director of DEBRA Research, a non-profit organization with a single-minded mission: to make EB curable. But DEBRA Research isn't a lab. It doesn't run clinical trials or make drugs. What it does is something arguably harder: it builds the ecosystem that makes drug development possible. Funding research, investing in biotech companies, building shared infrastructure, and connecting the right people at the right time. And the results are starting to show. They have a growing portfolio of investments, dedicated clinical trial infrastructure, and a seat at the table in deals that are moving the needle for patients who have waited long enough. · 01:46 Meet Martin Steiner · 03:32 What is DEBRA Research · 04:55 What it means to live with EB · 07:43 DEBRA Research's role in the drug development ecosystem · 12:03 Why DEBRA Research invests in infrastructure · 20:26 Why DEBRA Research makes equity investments in biotech · 24:50 The Replay and LEO Pharma deal: how it came together · 30:33 Obstacles to enabling collaboration in rare disease · 34:50 Gene therapy and read-through molecules as therapeutic approaches · 37:36 Is the DEBRA Research model replicable for other rare diseases Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Gene therapy for skin diseases: A field still finding its footing Six exosome therapy companies driving development in the field Extracellular vesicles: a growing pipeline still searching for validation

The life sciences industry has always had one great meeting place, a few days in November where the deals get done, the partnerships form, and the direction of the industry quietly shifts. For more than three decades, that place has been BIO-Europe . But this year, something is changing. BIO-Europe has always been the destination for BD professionals and dealmakers. In 2026, it's expanding — broadening its scope to become what the organisers are calling the epicenter of biotech, with new content tracks covering regulatory strategy, clinical development, and manufacturing, new registration options, and a deliberate push to bring the entire biopharma C-suite into the BIO-Europe room. · 01:39 BIO-Europe's 32nd edition: what has kept it relevant · 05:28 The "epicenter of biotech" · 11:06 From three content tracks to seven · 13:31 Three new tracks: regulatory, clinical, and biomanufacturing · 15:45 The new content-only registration pass · 18:12 Why Cologne and what the city offers the event · 19:48 The social program at BIO-Europe · 24:54 Where to register and find more information This episode is presented with the support of the EBD Group . Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology Lisbon is calling: the BIO-Europe Startup Spotlight returns in March 2026

Today I’m delighted to welcome Andy Parker, CEO of Step Pharma . With over 25 years of experience across AstraZeneca, Shire, Zealand Pharma, and venture capital, Andy has led Step Pharma since 2019. The company is pioneering a targeted approach to cancer and blood disorders by inhibiting the enzyme CTPS1. Their lead candidate, dencatistat, blocks this pathway that certain cancer cells and activated immune cells rely on, while sparing healthy cells that use the related CTPS2 enzyme. In this episode, we’ll dive into the science behind this mechanism, explore Step Pharma’s expanding pipeline from lymphomas and solid tumours to essential thrombocythaemia, and discuss their recent €38 million Series C financing. We’ll also look ahead to the future of precision oncology. 01:17 Meet Andy Parker 06:12 The biotech ecosystem around Geneva 07:51 The CTPS1 enzyme and why cancer cells depend on it 14:08 Pipeline-in-a-product strategy across three indications 20:14 The series C: €38 million raise 25:41 Partnering with big pharma: possibilities and limits 28:11 The future of precision oncology and metabolic targeting Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Step Pharma and Concr to partner on cancer treatment Step Pharma moves into oncology clinical trials Step Pharma announces promising pre-clinical cancer data

Today I'm sitting down with Randy Teel, Ph.D., President and CEO of Arvinas, a clinical-stage biotech based in New Haven, Connecticut, that is doing something genuinely new in medicine. Arvinas is pioneering a technology called PROTAC protein degradation. It's a platform that doesn't just block disease-causing proteins, but eliminates them entirely using the body's own disposal system to do it. It's a fundamental shift in how we think about drug design, and it's now reached a historic milestone: the first PROTAC ever to succeed in a Phase 3 clinical trial, with a regulatory filing now in front of the FDA. 01:19 Meet Randy Teel 03:41 Stepping into the CEO role in February 2026 13:17 What is a PROTAC and how it works 17:37 Vepdegestrant and the first PROTAC approval 23:43 Balancing partnerships versus keeping control of assets 31:57 Key milestones to watch in the next 12–18 months Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: From undruggable to oral therapy: The rise of STAT6 degraders Big Pharma Strikes Megadeals In Targeted Protein Degradation This Biotech Destroys Cancer Proteins by Introducing Them to ‘Executioner’ Proteins

Today we welcome Brandy Wilkinson, CEO of GemPharmatech , and Rikki Feng, the company’s Neuroscience Pipeline Leader. Our discussion focuses on a persistent challenge in drug development: neurology’s stubbornly high clinical failure rates. GemPharmatech is tackling this head-on with proprietary models for Alzheimer’s, Parkinson’s, and blood-brain barrier transport that better mirror human disease biology. We explore why mouse models matter more in neurology than in other fields, the design principles behind these next-generation tools, and how smarter preclinical partnerships can help therapeutic developers de-risk programs earlier. 00:00 Welcome Brandy Wilkinson and Rikki Feng 03:17 GemPharmatech's mission 06:26 Why mouse models matter in neurology 11:11 Common translation gaps in neurology 18:09 Designing proprietary neurological disease models 25:45 Building stronger CRO strategic partnerships 33:58 An optimistic future of neuroscience research This episode was produced with the support of GemPharmatech . Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Neurological diseases R&D trends and breakthrough innovations Brain Awareness Week: could ongoing R&D spur neuroscience breakthroughs? 11 neuroscience biotech companies you should know about

This week we preview the BIO International Convention, starting next week in San Diego. This is the key partnering event of the year where biotechs connect with pharmaceutical companies and investors in partnering meetings, all to advance and fund innovative therapies. My guest is Werner Lanthaler, Founder and CEO of WLAN Holding. Werner spent 15 years as CEO of Evotec SE, scaling the company from 200 employees and €40 million revenue to over 5,000 staff and €800 million. He previously served as CFO of Intercell AG, overseeing its IPO and vaccine launch and today he leads investments and advisory in high-tech life sciences. Werner explains why partnering events like BIO are critical to advancing science in biopharma. He shares practical advice on how biotechs can prepare before the event, succeed on site, and follow up to turn meetings into partnerships. He offers clear, actionable strategies to optimize your BIO experience. 01:36 Meet Werner Lanthaler 06:48 The power of partnering 08:55 Uncovering unexpected value 13:43 Irreplaceable in-person trust 17:06 Smart pre-event planning 21:00 Strategic targeting 24:02 Relationship-first meetings 30:18 The importance of prompt, persistent follow-up Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Special Episode: The 2025 BIO International Convention The ABC of biotech partnerships How to optimize your biotech company for partnering, licensing, and business success

Today we’re diving into the world of corticosteroids and hormonal therapies — essential APIs that treat everything from asthma and autoimmune diseases to diabetes and endocrine disorders. These molecules may be decades old, but their manufacturing remains highly complex and critical to patients worldwide. Our guest is Olivier Roux, a Senior Director at Curia. He shares how Curia partners with both startups and big pharma to simplify steroid API challenges, solve supply issues, and prepare for next-generation innovations. If you want to understand what it really takes to bring these life-changing therapies to patients, stay tuned — this conversation is packed with insights you won’t want to miss. 01:39 Meet Olivier Roux 02:20 What corticosteroids and hormonal therapies are 04:40 Evolution of steroidal hormonal therapies 05:50 Common uses of corticosteroids today 07:40 Key drivers of market growth 10:06 Curia’s agile outsourcing solutions for steroids 16:05 Importance of particle size control for steroids 17:18 Aseptic processing and high potency handling This episode was produced with the support of Curia . Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Eight rare autoimmune diseases biotechs are fighting to treat A clearer path to relief: sinusitis treatments on the way Asthma study suggests lung scarring may be reversible

Welcome to episode 200! Today I’m delighted to welcome back a very special guest: Joachim Eeckhout, the co-founder of Labiotech, co-owner of Knowbio, and founder of The Science Marketer. Joachim tells the Labiotech story, one of vision, persistence, and a deep belief that the European life-sciences sector deserved better storytelling. We go back to the very beginning with someone who was there: the frustrations, a bike tour of France that became legendary, the leap to Berlin, the fundraising rounds, the acquisition, and the launch of this very podcast. We’ll also hear where Joachim is today with his new ventures, his candid take on the current biotech media landscape in Europe, and what he sees coming next for science communication and media in our industry. 01:30: Meet Joachim Eeckhout 02:19: Early attraction to media creation 04:32: Founding story of Labiotech platform 06:35: Bike tour visiting biotech CEOs 11:21: Identifying larger European market opportunity 19:55: Raising seed funding for growth 24:20: Acquisition by Inpart in 2021 30:48: Current work with Knowbio 38:57: Future plans for Knowbio and biotech media Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Connecting the R&D ecosystem: 150 days into the integration of Inova, IN-PART and Labiotech We raised our second financing round to become the largest biotech media 🚀 How you can get involved in helping the industry–academia community solve global challenges

Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics . With World MS Day being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclerosis — a disease that affects nearly three million people worldwide and still leaves many patients searching for better options. In today’s episode Daniel shares his own journey into biotechnology, walk us through what life with MS really looks like for patients, and explain the science behind Immunic’s most advanced program, IMU-838. We discuss what makes Immunic’s oral therapy different from today’s treatments, uncover the latest data from the CALLIPER and ENSURE trials, and talk about what the future of MS care could look like. 01:22 Meet Daniel Vitt 04:54 Understanding multiple sclerosis 07:53 Evolution of the MS treatment landscape 12:08 Immunic’s lead MS therapy explained 22:57 World MS Day and what's next for Immunic Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: 11 neuroscience biotech companies you should know about The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval Six biotech companies advancing multiple sclerosis therapies

Today I am welcoming two guests: Quin Wills , CEO of Ochre Bio , a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges , CEO of Lexogen , an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence. 00:55 : The challenges of liver disease 04:44 : How Lexogen supports NGS drug discovery 07:29 : Major transcriptomics developments 10:05 : Designing high quality AI data 15:47 : How the Ochre-Lexogen partnership began 17:17 : Why a specialist partner is essential for scale 18:21 : Lexogen delivers on the massive sequencing project 21:50 : Why high quality data is crucial 27:02 : Lexogen's role in AI discovery 34:51 : Future plans and directions This episode was produced with the support of Lexogen . Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Deep phenotyping brings accuracy to precision medicine Spatial Transcriptomics: A window into disease Spatial Transcriptomics Landscape Shifts With Two Major Acquisitions

Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start , and we're going to challenge a few long-held beliefs about how starting material should be handled. My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at Cryoport Systems . Dominic has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. So, he's seen where things break and what actually works. I hope you enjoy my conversation with Dominic Clark. 01:07 Meet Dominic Clarke and Cryoport Systems 06:24 Fresh cells versus frozen cells 08:21 Why teams switch to cryopreservation late 12:37 The challenge of variability 16:47 IntegriCell when you already have a process in place 22:17 An argument for cryopreservation based on data 25:56 The future of IntegriCell and Cryoport Systems This episode is brought to you with the support of Cryoport Systems . Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: IntegriCell® Cryopreservation Cryoport Systems on the state of the ATMP market and the importance of supply chain resilience Cracking the code: Delivering biotherapeutics successfully across EMEA

Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of Lab Thread . Ryan's journey spans groundbreaking work in virotherapy and gene delivery during his D.Phil at Oxford, to founding OXGENE, a cell and gene therapy innovator acquired by WuXi Advanced Therapies in 2021. We'll explore the frustrations of fragmented lab tools that inspired Lab Thread's integrated digital solution—combining ELN, LIMS, molecular biology, and collaboration in one seamless platform. We’ll uncover how it boosts reproducibility, ensures compliance, and frees scientists for innovation, with accessible pricing for academics and biotechs. I hope you enjoy Ryan’s insights on evolving digital workflows and accelerating breakthroughs in the lab. 01:51: Meet Ryan Cawood 02:31: Frustrations with early digital tools. 03:19: Daily lab organization challenges. 06:50: Time lost to admin tasks. 11:09: Genesis of the Lab Thread concept. 13:53: Integrated workflow functionality explained. 17:23: Enhancing experiment reproducibility methods. 20:37: Achieving compliance standards easily. 26:10: The future of digital lab management. 28:33: Accelerating scientific breakthroughs. This episode is brought to you with the support of Lab Thread . Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Lab Thread - Your Lab, Connected Hiding in plain sight: how to solve bioscience’s software problem Lab chaos and digital dreams

This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epicrispr. Epicrispr is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. In this episode we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions. 01:43 Meet Stanley Qi 03:32 Founding Epicrispr 05:53 CRISPR interference and epigenome explained 10:04 Overview of GEMS gene modulation system 11:28 Reversibility and safety of epigenetic edits 18:42 Strategy for tackling multiple disease conditions 23:27 Clinical trial plans for EPI-321 candidate 30:06 Looking forward This episode is brought to you with the support of MedChemExpress . Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Could CRISPR really cure these diseases? 10 gene therapy companies you should know about CRISPR technology’s next wave: Ten companies to watch